AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Al...(E Mark certified) India Taiwan Korea Vie...)

Date:9/18/2009

E Mark certified), India, Taiwan, Korea, Vietnam, and in Chile (research use); approved in the US for the monitoring of colorectal cancer (CRC); approved in Canada (by Health Canada) for lung cancer detection and lung cancer treatment monitoring; and in many key markets, has the potential to be used as a general cancer screening test.

Radient Pharmaceuticals is selling the Onko-Sure(TM) to healthcare distribution partners in key markets around the world. Distribution partners market and sell the kits to hospitals, clinical labs, and other healthcare venues (both public and private) that provide testing services to patients via appropriate healthcare professionals. The Company also continues to sell kits directly (outside the USA) to select research centers for continuing studies and diagnostic research use. Cost per test to patients and reimbursement rates vary country to country. Radient Pharmaceuticals is also aggressively exploring further expansion of test use in private screening clinics in select strategic markets.

By 2010 the Company anticipates the launch of a rapid test version of Onko-Sure(TM) to further increase market share. The rapid test will provide the flexibility and cost effective deployment to significantly expand cancer testing and provide diagnostic solutions in emerging markets and economies addressing large underserved at-risk populations.

By late 2011 the Company anticipates launching a next generation version of Onko-Sure(TM) which is expected to deliver increased sensitivity and specificity; therefore garnering increased test kit price points. US market launch expected in 2012.

Elleuxe(TM): a therapeutic, high-end skin care product line based on the active ingredient 'Elleuxe Protein' - Radient Pharmaceutical's proprietary active ingredient that offers cell renewing properties designed to minimize the appearance of aging.

• The
  '/>"/>

SOURCE AMDL Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. LCA-Vision Announces CEO Resignation
2. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
3. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
4. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
5. Aethlon Medical, Inc. Announces Annual Meeting Results
6. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
7. Martek Announces Addition to Its Board of Directors
8. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member
9. BVGH Announces New Board Chair
10. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
11. Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta